pGPU6-GFP-survivin-shRNA表达载体的构建及其对卵巢癌HO8910PM细胞凋亡作用的探讨
|
摘要
背景与目的:近年来,人们对肿瘤的研究逐步向分子领域延伸,以期通过基因治疗达到治愈肿瘤的目的。细胞凋亡调控的紊乱是肿瘤发生、发展的一个重要环节,其中凋亡抑制蛋白家族(Inhibitor of apoptosisproteins,IAPs)是一个研究热点。Survivin基因是IAPs中的一个新成员,具有抑制细胞凋亡和促进细胞增殖的活性,通过直接或间接抑制caspase3和caspase7活性等途径阻断各种刺激诱导的细胞凋亡。RNA干扰(RNAi)是当前应用在逆向遗传学研究中高效的基因沉默技术,能高效特异地阻断基因的表达。目前,有关siRNA沉默survivin基因对卵巢癌H08910PM细胞凋亡作用的研究还鲜有报道。本实验意在研究Survivin-shRNA对survivin的沉默效应在卵巢癌细胞H08910PM中的作用,为卵巢癌基因治疗奠定一定的基础。
方法:研究对象为人卵巢癌H08910PM细胞株。(1)设计并构建针对survivin的siRNA真核表达质粒载体;(2)培养H08910PM细胞,以脂质体法转染细胞,设计空白对照组(Blank组)、阴性对照组(NC组,pGPU6-GFP-NC质粒转染细胞)、转染试剂对照组(MOCK组)、sur-shRNA组(pGPU6-GFP-survivin-shRNA质粒转染细胞);(3)实时荧光定量PCR检测survivin mgAN表达水平;(4)流式细胞术检测细胞凋亡和细胞周期情况;(5)Western blot检测survivin蛋白的表达量。
结果:(1)重组质粒表达载体pGPU6-GFP-survivin-shRNA经酶切、测序鉴定,证实插入载体目的基因片段大小与插入方向正确;(2)通过脂质体介导转染人卵巢癌H08910PM细胞,在荧光显微镜下观察到绿色荧光。(3)实时荧光定量PCR结果证实干扰组的HO-8910PM细胞在48h和72h survivin mRNA表达量下降了38%和57%,与blank组相比有统计学意义(P＜0.05),48h到72h干扰片段的沉默效应呈增强趋势;(4)流式细胞术检测,细胞的转染率为52.26%,在48h和72h sur-shRNA组细胞凋亡率(30.78±0.68和38.47±0.84)高于Blank组(2.15±0.78和2.74±0.55)(P＜0.05);NC组(2.87±0.81和3.67±0.29),MOCK组(3.38±0.56和3.88±0.25)和Blank组比无差异(P＜0.05):(5)PI单染流式细胞仪检测细胞周期结果证实sur-shRNA组细胞周期发生改变,转染后G_0/G_1期细胞数显著增加,与Blank组相比出现G_0/G_1期阻滞现象,G_0/G_1期升高而G_2/M期下降(P＜0.05)。(6)Western blot结果证实了转染pGPU6-GFP-survivin-shRNA的H08910PM细胞SUrvivin蛋白的量明显下调。
结论:(1)针对survivin基因的pGPU6-GFP-survivin-shRNA表达载体构建成功。(2)针对survivin基因的shRNA可明显降低卵巢癌H08910PM细胞survivin基因mRNA及蛋白的表达。(3)针对survivin基因的shRNA可促进H08910PM细胞的凋亡,将细胞阻滞于G_0/G_1期。本实验构建的重组质粒能有效沉默survivn基因的表达,并能促进H08910PM细胞的凋亡和抑制细胞增殖,为卵巢癌基因治疗奠定了一定的基础。
Background and objective:In recent years,people research on cancer gradually extended to the field of molecular,with a view to cure through gene therapy to achieve the purpose of tumor.Disordered regulation of apoptosis are the tumor occurrence and development of an important aspect.Inhibitor of apoptosis protein family,which is a research hotspot.Survivin gene is a new member of the inhibitor of apoptosis protein family,which can inhibit apoptosis and promote cell proliferation activity,directly or indirectly through inhibition caspase3 and caspase7 activity to block apoptosis of a variety of ways induced.RNA interference is gene silencing technology which used in the reverse genetics studies,can be effective in blocking specific gene expression.At present,the siRNA silencing survivin gene on ovarian cancer cell apoptosis HO8910PM study also has been reported rarely.The experiment intended to study the survivin-siRNA silencing effect on human ovarian cancer HO8910PM cells,and lay the foundation for the ovarian carcer gene treatment.
Methods:The study used the human ovarian cancer cell HO8910PM;(1) A eukaryotic expression vector targeting on survivin siRNA was designed and constructed;(2) Cultured HO8910PM cells,then transfected into cells by Lipofectamine TM~(2000),and designed blank control group(black),negative control group(NC,pGPU6-GFP- NC transfected into cells),Lipofectamine TM~(2000) transfection group(mock),interference group(pGPU6-GFP-survivin-shRNA transfected into cells);(3) Expression level of survivin mRNA was assayed by real-time fluorescence quantitative PCR technology;(4)The apoptosis and cycle of cells were assessed by flow cytometry;(5) Expression level of survivin protein was assayed by Western bloting.
Results:(1) After the enzyme cutting and sequence identification,it was verified that the size and direction of objective gene segment inserting vector.(2) Liposome-mediated transfection of human ovarian cancer HO8910PM cell,green fluorescence was observed under in fluorescence microscopy.(3) The result of real time fluorescence quantitative RT-PCR indicated that expression of survivin mRNA of HO-8910PM cells transfects with the pGPU6-GFP-survivin-shRNA after 48 hours and 72 hours dropped by 38%and 57%,compared with the blank control had difference(P＜0.05),and the effect of silencing gradually enhances at 48 hours to 72 hours;(4)The FCM results showed that,the transfection rate was56.26%,at 48 hours to 72 hours the apoptotic rate in sur-shRNA group(30.78±0.68 and 38.47±0.84) higher than those in blank control group(2.15±0.78 and 2.74±0.55)(P＜0.05),NC group(2.87±0.81 and 3.67±0.29 ) and mock group(3.38±0.56 and 3.88±0.25) compara with blank control group had no difference(P＜0.05);(5) The FCM of PI simple staining indicated that sur-shRNA group could cause the number of cells to raise at the time of G_0/G_1 and decrease at the time of G_2/M(P＜0.05);(6) Western bloting results showed that expression of survivin proteinum of HO-8910PM cells transfects with the PGPU6/GFP/Neo/survivin-siRNA decreased obviously.
Conclusion:(1) Construct the shRNA expression vector of pGPU6-GFP-survivin -shRNA successfully;(2) Survivin shRNA targeting to survivin can effectively inhibit the expression of survivin mRNA and protein.(3) Survivin shRNA targeting to survivin can promote apoptosis of HO8910PM cells and enable the cell cycle of HO8910PM cells to appear G_0/G_1 phase arrest.The recombinant plasmid of this experiment can make survivn gene expression silence effectively,and promote the apoptosis of HO8910PM cells,inhibit cell proliferation.So it can selltle foundation for the ovarian carcer gene treatment.
方法:研究对象为人卵巢癌H08910PM细胞株。(1)设计并构建针对survivin的siRNA真核表达质粒载体;(2)培养H08910PM细胞,以脂质体法转染细胞,设计空白对照组(Blank组)、阴性对照组(NC组,pGPU6-GFP-NC质粒转染细胞)、转染试剂对照组(MOCK组)、sur-shRNA组(pGPU6-GFP-survivin-shRNA质粒转染细胞);(3)实时荧光定量PCR检测survivin mgAN表达水平;(4)流式细胞术检测细胞凋亡和细胞周期情况;(5)Western blot检测survivin蛋白的表达量。
结果:(1)重组质粒表达载体pGPU6-GFP-survivin-shRNA经酶切、测序鉴定,证实插入载体目的基因片段大小与插入方向正确;(2)通过脂质体介导转染人卵巢癌H08910PM细胞,在荧光显微镜下观察到绿色荧光。(3)实时荧光定量PCR结果证实干扰组的HO-8910PM细胞在48h和72h survivin mRNA表达量下降了38%和57%,与blank组相比有统计学意义(P＜0.05),48h到72h干扰片段的沉默效应呈增强趋势;(4)流式细胞术检测,细胞的转染率为52.26%,在48h和72h sur-shRNA组细胞凋亡率(30.78±0.68和38.47±0.84)高于Blank组(2.15±0.78和2.74±0.55)(P＜0.05);NC组(2.87±0.81和3.67±0.29),MOCK组(3.38±0.56和3.88±0.25)和Blank组比无差异(P＜0.05):(5)PI单染流式细胞仪检测细胞周期结果证实sur-shRNA组细胞周期发生改变,转染后G_0/G_1期细胞数显著增加,与Blank组相比出现G_0/G_1期阻滞现象,G_0/G_1期升高而G_2/M期下降(P＜0.05)。(6)Western blot结果证实了转染pGPU6-GFP-survivin-shRNA的H08910PM细胞SUrvivin蛋白的量明显下调。
结论:(1)针对survivin基因的pGPU6-GFP-survivin-shRNA表达载体构建成功。(2)针对survivin基因的shRNA可明显降低卵巢癌H08910PM细胞survivin基因mRNA及蛋白的表达。(3)针对survivin基因的shRNA可促进H08910PM细胞的凋亡,将细胞阻滞于G_0/G_1期。本实验构建的重组质粒能有效沉默survivn基因的表达,并能促进H08910PM细胞的凋亡和抑制细胞增殖,为卵巢癌基因治疗奠定了一定的基础。
Background and objective:In recent years,people research on cancer gradually extended to the field of molecular,with a view to cure through gene therapy to achieve the purpose of tumor.Disordered regulation of apoptosis are the tumor occurrence and development of an important aspect.Inhibitor of apoptosis protein family,which is a research hotspot.Survivin gene is a new member of the inhibitor of apoptosis protein family,which can inhibit apoptosis and promote cell proliferation activity,directly or indirectly through inhibition caspase3 and caspase7 activity to block apoptosis of a variety of ways induced.RNA interference is gene silencing technology which used in the reverse genetics studies,can be effective in blocking specific gene expression.At present,the siRNA silencing survivin gene on ovarian cancer cell apoptosis HO8910PM study also has been reported rarely.The experiment intended to study the survivin-siRNA silencing effect on human ovarian cancer HO8910PM cells,and lay the foundation for the ovarian carcer gene treatment.
Methods:The study used the human ovarian cancer cell HO8910PM;(1) A eukaryotic expression vector targeting on survivin siRNA was designed and constructed;(2) Cultured HO8910PM cells,then transfected into cells by Lipofectamine TM~(2000),and designed blank control group(black),negative control group(NC,pGPU6-GFP- NC transfected into cells),Lipofectamine TM~(2000) transfection group(mock),interference group(pGPU6-GFP-survivin-shRNA transfected into cells);(3) Expression level of survivin mRNA was assayed by real-time fluorescence quantitative PCR technology;(4)The apoptosis and cycle of cells were assessed by flow cytometry;(5) Expression level of survivin protein was assayed by Western bloting.
Results:(1) After the enzyme cutting and sequence identification,it was verified that the size and direction of objective gene segment inserting vector.(2) Liposome-mediated transfection of human ovarian cancer HO8910PM cell,green fluorescence was observed under in fluorescence microscopy.(3) The result of real time fluorescence quantitative RT-PCR indicated that expression of survivin mRNA of HO-8910PM cells transfects with the pGPU6-GFP-survivin-shRNA after 48 hours and 72 hours dropped by 38%and 57%,compared with the blank control had difference(P＜0.05),and the effect of silencing gradually enhances at 48 hours to 72 hours;(4)The FCM results showed that,the transfection rate was56.26%,at 48 hours to 72 hours the apoptotic rate in sur-shRNA group(30.78±0.68 and 38.47±0.84) higher than those in blank control group(2.15±0.78 and 2.74±0.55)(P＜0.05),NC group(2.87±0.81 and 3.67±0.29 ) and mock group(3.38±0.56 and 3.88±0.25) compara with blank control group had no difference(P＜0.05);(5) The FCM of PI simple staining indicated that sur-shRNA group could cause the number of cells to raise at the time of G_0/G_1 and decrease at the time of G_2/M(P＜0.05);(6) Western bloting results showed that expression of survivin proteinum of HO-8910PM cells transfects with the PGPU6/GFP/Neo/survivin-siRNA decreased obviously.
Conclusion:(1) Construct the shRNA expression vector of pGPU6-GFP-survivin -shRNA successfully;(2) Survivin shRNA targeting to survivin can effectively inhibit the expression of survivin mRNA and protein.(3) Survivin shRNA targeting to survivin can promote apoptosis of HO8910PM cells and enable the cell cycle of HO8910PM cells to appear G_0/G_1 phase arrest.The recombinant plasmid of this experiment can make survivn gene expression silence effectively,and promote the apoptosis of HO8910PM cells,inhibit cell proliferation.So it can selltle foundation for the ovarian carcer gene treatment.
引文
[1]Majno G,Joris I.Apoptosis,Oncosis and necrosis:an overview of cell death_[J].Am J Pathol,1995,146(1):3-15.
[2]AffordS,Randhawa5.APoPtosis.MolPathol,2000,53(2):55-63.
[3]Rohayem J,Diestelkoeller P,Weigle B,et al.Antibody response to the tumor associated inhibitor of apoptosis protein surviving in cancer patients[J].Cancer Res,2000,60(7):1815-1817.
[4]Altieri DC.A novel anti-apoptisis gene,survivin,expressed in cancer and lymphoma J.Nat Med,1997,(8):917-921.
[5]Schmidt SM,Schag K,Muller MR,et al.Survivin is a shared tumor-associated an -tigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells[J].Blood,2003,102(2):571- 576.
[6]Marzia Pennati,Marco Folini,and Nadia Zaffaroni.Targeting survivin in cancer therapy:fulfilled promises and open questions.Carcinogenesis.Jun 2007;28:1133-1139.
[7]Philipp Lechler,Xiaoqing Wu,Wanja Bernhardt.et al.The Tumor Gene Survivin Is Highly Expressed in Adult Renal Tubular Cells:Implications for a Pathophysiological Role in the Kidney.Am.J.Pathol.,Nov 2007;171:1483 - 1498.
[8]JohnsonME,Howerth EW.Survivin:a bifunctional inhibitor of apop tosis protein [J].Vet Pathol,2004,41(6):599 - 607
[9]张欣,吴令英,徐宁志,凋亡抑制蛋白与卵巢癌化疗耐药.癌症进展杂志,2005年7月第3卷第4期,338-341.
[10]Yonesaka K,Tamura K,Kurata T,et al.Small interferingRNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin[J].Int J Cancer,2006,118(4):812- 820.
[11]施渺筱,宋宝安。Survivin与卵巢癌的研究进展 中国民康医药2006年6月第18卷下半月第6期
[12]Sui L,Dong Y,Ohno M,et al.Survivin expression and it scorrelation wit h cell proliferation and prognosis in epithelial ovarian tumors[J].Int J Oncol,2002,21 (2):315-320.
[13]张淑兰,赵长青,林蓓,等。凋亡抑制基因Survivin在卵巢上皮性癌组织中的表达及其与bcl-2/bax蛋白表达的关系(J).中华妇产科杂志,2003,38:2032051
[14]FalleniM,Pellegrini C,Marchetti A,et al.Survivin gene xpression in early stage on sm all cell lung cancer[J].J Pathol,2003,200(5):620- 626.
[15]Wang Zhang-xiang,Sampath J,Fukuda S,et al.Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis[J].Cancer Res,2005,65(18):8224- 8232.
[16]Wurl P,Kappler M,Meye A,et al.Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma[J]Lancet,2002,359(9310):943- 945.
[17]Uchida H,Tanaka T,Sasaki K,et al.Adenovims - mediated transfer Of siRNA against Survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo[J].Mol Ther,2004,10:162-171.
[18]Downward J.RNA interference[J].BMJ.2004.328:1245- 1248.
[19]Scherr M,Morgen MA,Eder M.Gene silencing mediated by small interfering RNAs in mammalian cells[J].Curr Med Chem,2003.10:245 - 256.
[20]Huynh T,Walchli S,Sioud M.Transcriptional targeting of small interfering RNAs into cancer cells[J].Biochem Biophys Res Commun,2006,350(4):854-859.
[21]1.LJave C.,Xie Z.,Kasschau K.D.et al.Cleavage of seaEecrow--like mRNA targets directed by a class of Arabidopsis miRNA.Science,2002,297:2053-2056
[22]宋现让,柳永蕾,刘贤锡,等.质粒载体系统介导的人肿瘤细胞RNA干扰作用[J].基础医学与临床,2005,25(9):807-812.
[23]Harborth J,Elbashir SM,Beehert K,etal.Identifieation of essential genesin cultured mammalian cell susingsmall interfering RNAs[J].J Cell Sei,2001,114(Pt24):4557-4565.
[24]AltieriDC.Validating survivin as a cancer therapeutic target[J].Nat Rev Cancer,2003,3:46254
[25]Ling X,Yang J,Tan D F,et al.Diferential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non -small-cell lungcancer(NSCLC)[J].Lung Cancer,2005,49(3):353-361.
[26]Li F.Ling X.Survivin study:An update of"What is the next wave?"[J].J Cellular Physiol,2006,208(3):476-486.
[27]Ichiki Y,Hanagiri T,Takenoyama M,et al.Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy[J].Lung Cancer,2005,48t2):281-289.
[28]MiyagishM,TairaK.U6Promoter-driven siRNAs with four uridine3'overhangs efficiently suppress argeted gene expression in mammaliance ceells[J].Nat Bioteclnol,2002,20(5):497-500.
[29]Sui G,Soohoo C,Affar E B,Gay F,Shi Y,Forrester WC,Shi Y.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.Proc Natl Acad Sci USA.2002,99(8):5515-5520
[30]Yu J Y,Taylor J,DeRuiter SL.Turner.D L.Simultaneous inhibition of GSK 3alpha and GSK3beta using hairpin siRNA expression vectors.Mol Ther,2003,7(2):228-236
[31]Stewart S A,Dykxhoorn D M,Palliser D,Mizuno H,Yu E Y,An D S,Sabatini D M,Chen I S,Hahn W C,Sharp P A,Weinberg R A,Novina C D.Lentivirus delivered stable gene silencing by RNAi in primary cells.RNA,2003,9(4):493-501
[32]Tiscornia G,Singer O,Ikawa M,Verma I M.A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.Proc Natl Acad Sci USA,2003,100(4):1844-1848
[33]Hemann M T,Fidman J S,Zilfou J T,Hemando E,Paddison P,Cordon-Cardo C,Hannon GJ,Lowe S W.An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.Nat Genet,2003,33(3):396-400
[34]Brummelkamp TR,Bernards R,Agami R...A system for stable expression of short interfering RNA in mammaliance cells[J].Seiense,2002,296(5567):550-553.
[35]Huynh T,Walchli S,Sioud M.Transcriptional targeting of small interfering RNAs into cancer cells[J].Biochem Biophys Res Commun,2006,350(4):854-859.
[36]宋艳斌,马文丽,冯春琼,等.应用RNA干扰技术抑制K562细胞BCR2ABL表达及诱导细胞凋亡[J].基础医学与临床,2005,25(7):620-623.
[37]危敏,马文丽,张宝,等.siRNA抑制HPV18E6基因及对HeLa细胞凋亡的影响[J].基础医学与临床,2006,26(10):1112-1117.
[38]Kato M,Mc Donald K J,Khan S,e tal.Expression of human DEC-205(CD 205)multilectin receptor on leukocytes[J].Intlm munol,2006,18(6):857-869.
[39]AltieriDC.Validating survivin as a cancer therapeutic target[J].Nat Rev Cancer,2003,3:46254
[40]Scherer L,Rossi JJ.Therapeutic applications of RNA interference:recent advances in siRNA design[J].Adv Genet.2004.52:1- 21.
[41]Hannon GJ.RNA interference[J].Nature.2002,418(6894):244-251.
[42]Hammond SM.Bemstein E,Beach D.et al.An RNA-directed nuctease mediates post - transcriptional gene silencing in Drosophila cells[J].Nature,2000,404(6775):293-296.
[43]倪虹,丁显平:曾索,靶向Survivin的shRNA表达载体的构建和对宫颈癌Caski细胞Survivin表达的影响现代预防医学2008年第35卷,第14期,2738-3741
[44]WakanaY,KasuyaK,KatayanagiS et al.Effectofsurviving on allprolif-eration and apoptosis in gastric cancer.OncolRes,2002,9(6):1213
[45]Emens LA.Survivin and cancer[J].Cancer Biol Ther,2004,3(2):180- 183.
[46]赵杨,温放,于月新等,survivin mRNA和caspase3 mRNA在卵巢上皮性癌中的表达及意义.中国医科大学学报,第35卷,第1期,2006年2月63-64
[47]Tamm I,Wang Y,Sausville E,et al.IAP - family protein survivin in2hibits caspase activity and apoptosis induced by Fas(CD95),Bax,cas2pases,and anticancer drugs[J].Cancer Res,1998,58(23):5315-5320,
[48]Suzuki A,Ito T,Kawano H,et al.survivin initiates procaspase 3/P21complex formation as a result of interaction with Cdk4 to resist Fas -mediated cell death[J].Oncogene,2000,19(10):1346-1353.
[49]Pietenpol JA,Stewart.ZA.Cell cycle checkpoint signaling:Cell cycle arrest versus apoptosis[J].Toxicology,2002,27(1812182):475 - 481
[50]史惠蓉,兰莉,乔玉环,等.卵巢癌组织中Survivin和PCNA的表达[J].郑州大学学报(医学版),2004;39(4):552-554.
[1]Salvesen GS,Duckett CS. IAP p roteins: blocking the road to death's door[ J ]. Nat RevMol Cell Biol, 2002, 3 (6) : 401 - 410.
[2]Altieri DC.A novel anti-apoptisis gene ,survivin,expressed in cancer and lymphoma J .Nat Med,1997,(8):917-921.
[3]Mahotka C,Wenzel M,Springer E, et al .Survivin-delta Ex3 and surviving-2B:two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.Cancer Res 1999,Decl5;59(24):6097-6102. Res,1998,Decl;58(23):5315-5320.
[4] Caldas,H. et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene, 2005, 24, 1994-2007.
[5]Caldas,H. et al. Survivin 2alpha: a novel survivin splice variantexpressed in human malignancies. Mol. Cancer, 2005,4,11.
[6]Iamml, WangY, SausvilleED, etal.lAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs. Caneer Res, 1988, 58:5315-5320
[8]Cryns,V. et al. Proteases to die for. Genes Dev., 1999,12,1551-1570.
[9]Deveraux,Q.L. et al. IAP family proteins—suppressors of apoptosis.Genes Dev.,1999,13,239-252.
[10] Li,F. et al. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycledependent expression.Cancer Res., 1999,59,3143-3151.
[11]chen J, Wu W,Tahir SK, et al.Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage- independent growth.NeoPlasia, 2000, 2(3):235-241
[12] O'Connor DS, SehechnerJS, AdidaC, et al.Control of apoptosis cells.Am J Pathol, 2000, 156(2):393-398
[13]LI F, Ambrosini G, Chu EY, et al.Control of aoptosis and mitotic spindle checkpoint by surviving.Nature, 1998, 396(6711):580-584
[14] Fukuda,S. et al. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Then, (2006) 5,1087-1098.
[15]Mesri,M. et al. Suppression of vascular endothelial growth factormediated endothelial cell protection by survivin targeting. Am. J. Pathol.(2001) 158,1757-1765.
[16] Altznauer,F. et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med. (2004)199,1343-1354.
[17]Xing,Z. et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med., (2004)199, 69-80.
[18]Gurbuxani,S. et al. Differential requirements for survivin in hematopoietic cell development. Proc. Natl Acad. Sci. USA, (2005) 102, 11480-11485.
[19]Fukuda,S. et al. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(t) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood, (2001)98.2091-2100.
[20]Deguchi,M. et al. Expression of survivin during liver regeneration. Biochem.Biophys. Res. Commun., (2002) 297, 59-64.
[21] Chiou,S.K. et al. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem. Biophys. Res. Commun., (2003) 305, 374-379.
[22]Wang,Y. et al. Survivin expression in rat testis is up-regulated by stem-cell factor.Mol. Cell Endocrinol., (2004) 218, 165-174.
[23]Altieri,D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, (2003) 22, 8581-8589.
[24]Florrel,S.R. et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J. Cutan. Pathol., (2005) 32, 45-49.
[25]Vetter,C.S. et al. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch. Dermatol. Res. (2005) 297, 26-30.
[26]Rohayem J, Diestelkoetter P, Weigle B, et al.Antibody response to the tumor-associated inhibitor of apoptosis protein surviving in cancer patients.Cancer Res, 2000, 60:1815-1817
[27]Tanaka K, Iwamoto S, Gon G, et al.Expression of surviving and its relationship to loss of apoptosis in breast carcinomas.Clin Caneer Res, 2000, 6:127-134
[28]Grosstnan D, McNiff JM, LiF, et al.Expression and targeting of the apoptosis inhibitor, surviving, inhuman melanoma.J Invest Dermatol, 1993, 113(6): 1076-1081
[29]Monzo M, jRosell R, Felip E, Astudillo J, et al.A novel Anti-apoptosis gene:re-expression of surviving messenger RNA as a prognosis marker in non-small-cell Lung cancers.J Clin Oncol, 1999, 17(7):2100-2104
[30]Olie RA, Simoes-Wust AP.Baumann B, et al.Anovel antisense oligonucleotide Targeting surviving expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.Cancer Res, 2000, 60:2805-2809
[31]SaitohY, YaaginumaY, Ishvikawa M.Analysis of Bel-2, Bax and Survivin genes in uterin cancer.Int J Oneol, 1999, 5(1):137-141.
[32]Tringler B, Lehner R, Shroyer KR, etal. Immunohistochemical Loealization of survivin in Serous tumors of the ovary.Appl Immunohistochem Mol Mophol, 2004,Mar:12(1):40-43
[33]Sui L, Dong Y, Ohno M, etal. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.Int J Oncol ,2002:21(2):315-320.
[34]Ambrosini G, Adida C, Sirugo G, et al.Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.J.BiolChem, 1998 Mayl: 273 (18):11177-11182.
[35]Mesri M,Wall NR, LiJ, et al. Cancer genethera by using a survivin mutant adenovirus [J].J Clinhivest, 2001, Oct;108(7):981-990.
[36]Sehmitz M, Diestelkoetter P, weigle B, et al.Gene ration of surviving-specific CD8+T effeetor cells by dendritic cells pulsed with Protein or selected peptides.Caneer Res, 2000, 60(17):4845-4849
[37]Cogoni C, Maeino G.Post-transcriptional gene silencing across kingdoms[J].Genes Dev, 2000, 10:638-643.
[38]Guru T.A silence that speaks volumes[J].Nature, 2000, 404:804-808.
[39]Hammond SM, Caudy AA, Harmon GJ.Post-transcriptional gene sileneing by double- stranded RNA[J].Nature Rev Gen, 2001, 2:110-119.
[40]Napoli C.Lemieux C, Jorgensen R.Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression ofhomologous genes in trans[J] .Plant Cell, 1990, 2:279-289.
[41]Jorgensen RA, Cluster PD, English J, et al.Chalcone synthase cosuppression phenotypes in petunia fiowersxomparison of sensevs, antisense constructs and single-copy vs, complext-DNAs equences[J] .Plant Mol Biol, 1996, 31:957-973.
[42]Ingelbreeht 1, Van Houdt H, Van Montagu M, et al.Posttranscriptional silencing of reporter trans genes in tobacco correlateswith DNA methylation[J].Proc Nat lAcad Sci USA, 1994, 91:10502-10506.
[43]Cogoni C, Irelan JT, Sehumaehe M, et al.Transgene silencing of theal-1 gene in vegetative cells of Neurospora is mediated by cytoplasmic effector and does not depend on DNA-DNA interactions or DNA methylation[J]. EMBOJ , 1996,15:3153-3163.
[44]Guo S, Kempheus KJ.Par-1, a gene required for establishing polarity in C.elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed [J].Cell, 1995, 81:611-620.
[45]Fire A, Xu S, Montgomery MK, et al.Potent an dspecific genetic interference by Double-stranded RNA in Caenothabditis elegans[J].Nature, 391:806-811.
[46]Timmons L, Fire A.Spceific interference by ingested dsRNA[J].Natufe, 1998,395:854.
[47]Timmons L, Court D, Fire A.Ingestion of baeterially expressed dsRNAs can produce spceific and potent genetic interference in Caenothabditis elegans [J]. Gene,263:103-112.
[48]Hunter CP.Shrinking the black box of RNAi[J].Current Biology, 2000 , 10:R137-R140.
[49]Sharp PA.RNA interference-2001[J].Genes Dev, 2001, 15:485-490.
[50]Hamilton AJ,Baulcombe DC.A species of small antisense RNA in posttranseriptional gene silencingin plants[J].Scienee,1999,286:950-952.[51]Zamore PD,Tuschl T,Sharp PA,et al.RNAi:double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21to23 nucleotide intervals[J].Cell,2000,101:25-33.
[52]Hutvagner G,Zamore PD.RNAi:nature abhors a double-strand[J].Curr Opin Genetics & Development,2002,12:225-232.
[53]Nykanen A,Haley B,Zamorep D.ATP requirements and small interfering RNA structure in the RNA interferenee pathway[J].Cell,2001,107:309-321.
[2]AffordS,Randhawa5.APoPtosis.MolPathol,2000,53(2):55-63.
[3]Rohayem J,Diestelkoeller P,Weigle B,et al.Antibody response to the tumor associated inhibitor of apoptosis protein surviving in cancer patients[J].Cancer Res,2000,60(7):1815-1817.
[4]Altieri DC.A novel anti-apoptisis gene,survivin,expressed in cancer and lymphoma J.Nat Med,1997,(8):917-921.
[5]Schmidt SM,Schag K,Muller MR,et al.Survivin is a shared tumor-associated an -tigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells[J].Blood,2003,102(2):571- 576.
[6]Marzia Pennati,Marco Folini,and Nadia Zaffaroni.Targeting survivin in cancer therapy:fulfilled promises and open questions.Carcinogenesis.Jun 2007;28:1133-1139.
[7]Philipp Lechler,Xiaoqing Wu,Wanja Bernhardt.et al.The Tumor Gene Survivin Is Highly Expressed in Adult Renal Tubular Cells:Implications for a Pathophysiological Role in the Kidney.Am.J.Pathol.,Nov 2007;171:1483 - 1498.
[8]JohnsonME,Howerth EW.Survivin:a bifunctional inhibitor of apop tosis protein [J].Vet Pathol,2004,41(6):599 - 607
[9]张欣,吴令英,徐宁志,凋亡抑制蛋白与卵巢癌化疗耐药.癌症进展杂志,2005年7月第3卷第4期,338-341.
[10]Yonesaka K,Tamura K,Kurata T,et al.Small interferingRNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin[J].Int J Cancer,2006,118(4):812- 820.
[11]施渺筱,宋宝安。Survivin与卵巢癌的研究进展 中国民康医药2006年6月第18卷下半月第6期
[12]Sui L,Dong Y,Ohno M,et al.Survivin expression and it scorrelation wit h cell proliferation and prognosis in epithelial ovarian tumors[J].Int J Oncol,2002,21 (2):315-320.
[13]张淑兰,赵长青,林蓓,等。凋亡抑制基因Survivin在卵巢上皮性癌组织中的表达及其与bcl-2/bax蛋白表达的关系(J).中华妇产科杂志,2003,38:2032051
[14]FalleniM,Pellegrini C,Marchetti A,et al.Survivin gene xpression in early stage on sm all cell lung cancer[J].J Pathol,2003,200(5):620- 626.
[15]Wang Zhang-xiang,Sampath J,Fukuda S,et al.Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis[J].Cancer Res,2005,65(18):8224- 8232.
[16]Wurl P,Kappler M,Meye A,et al.Co-expression of survivin and TERT and risk of tumour-related death in patients with soft-tissue sarcoma[J]Lancet,2002,359(9310):943- 945.
[17]Uchida H,Tanaka T,Sasaki K,et al.Adenovims - mediated transfer Of siRNA against Survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo[J].Mol Ther,2004,10:162-171.
[18]Downward J.RNA interference[J].BMJ.2004.328:1245- 1248.
[19]Scherr M,Morgen MA,Eder M.Gene silencing mediated by small interfering RNAs in mammalian cells[J].Curr Med Chem,2003.10:245 - 256.
[20]Huynh T,Walchli S,Sioud M.Transcriptional targeting of small interfering RNAs into cancer cells[J].Biochem Biophys Res Commun,2006,350(4):854-859.
[21]1.LJave C.,Xie Z.,Kasschau K.D.et al.Cleavage of seaEecrow--like mRNA targets directed by a class of Arabidopsis miRNA.Science,2002,297:2053-2056
[22]宋现让,柳永蕾,刘贤锡,等.质粒载体系统介导的人肿瘤细胞RNA干扰作用[J].基础医学与临床,2005,25(9):807-812.
[23]Harborth J,Elbashir SM,Beehert K,etal.Identifieation of essential genesin cultured mammalian cell susingsmall interfering RNAs[J].J Cell Sei,2001,114(Pt24):4557-4565.
[24]AltieriDC.Validating survivin as a cancer therapeutic target[J].Nat Rev Cancer,2003,3:46254
[25]Ling X,Yang J,Tan D F,et al.Diferential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non -small-cell lungcancer(NSCLC)[J].Lung Cancer,2005,49(3):353-361.
[26]Li F.Ling X.Survivin study:An update of"What is the next wave?"[J].J Cellular Physiol,2006,208(3):476-486.
[27]Ichiki Y,Hanagiri T,Takenoyama M,et al.Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy[J].Lung Cancer,2005,48t2):281-289.
[28]MiyagishM,TairaK.U6Promoter-driven siRNAs with four uridine3'overhangs efficiently suppress argeted gene expression in mammaliance ceells[J].Nat Bioteclnol,2002,20(5):497-500.
[29]Sui G,Soohoo C,Affar E B,Gay F,Shi Y,Forrester WC,Shi Y.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.Proc Natl Acad Sci USA.2002,99(8):5515-5520
[30]Yu J Y,Taylor J,DeRuiter SL.Turner.D L.Simultaneous inhibition of GSK 3alpha and GSK3beta using hairpin siRNA expression vectors.Mol Ther,2003,7(2):228-236
[31]Stewart S A,Dykxhoorn D M,Palliser D,Mizuno H,Yu E Y,An D S,Sabatini D M,Chen I S,Hahn W C,Sharp P A,Weinberg R A,Novina C D.Lentivirus delivered stable gene silencing by RNAi in primary cells.RNA,2003,9(4):493-501
[32]Tiscornia G,Singer O,Ikawa M,Verma I M.A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.Proc Natl Acad Sci USA,2003,100(4):1844-1848
[33]Hemann M T,Fidman J S,Zilfou J T,Hemando E,Paddison P,Cordon-Cardo C,Hannon GJ,Lowe S W.An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo.Nat Genet,2003,33(3):396-400
[34]Brummelkamp TR,Bernards R,Agami R...A system for stable expression of short interfering RNA in mammaliance cells[J].Seiense,2002,296(5567):550-553.
[35]Huynh T,Walchli S,Sioud M.Transcriptional targeting of small interfering RNAs into cancer cells[J].Biochem Biophys Res Commun,2006,350(4):854-859.
[36]宋艳斌,马文丽,冯春琼,等.应用RNA干扰技术抑制K562细胞BCR2ABL表达及诱导细胞凋亡[J].基础医学与临床,2005,25(7):620-623.
[37]危敏,马文丽,张宝,等.siRNA抑制HPV18E6基因及对HeLa细胞凋亡的影响[J].基础医学与临床,2006,26(10):1112-1117.
[38]Kato M,Mc Donald K J,Khan S,e tal.Expression of human DEC-205(CD 205)multilectin receptor on leukocytes[J].Intlm munol,2006,18(6):857-869.
[39]AltieriDC.Validating survivin as a cancer therapeutic target[J].Nat Rev Cancer,2003,3:46254
[40]Scherer L,Rossi JJ.Therapeutic applications of RNA interference:recent advances in siRNA design[J].Adv Genet.2004.52:1- 21.
[41]Hannon GJ.RNA interference[J].Nature.2002,418(6894):244-251.
[42]Hammond SM.Bemstein E,Beach D.et al.An RNA-directed nuctease mediates post - transcriptional gene silencing in Drosophila cells[J].Nature,2000,404(6775):293-296.
[43]倪虹,丁显平:曾索,靶向Survivin的shRNA表达载体的构建和对宫颈癌Caski细胞Survivin表达的影响现代预防医学2008年第35卷,第14期,2738-3741
[44]WakanaY,KasuyaK,KatayanagiS et al.Effectofsurviving on allprolif-eration and apoptosis in gastric cancer.OncolRes,2002,9(6):1213
[45]Emens LA.Survivin and cancer[J].Cancer Biol Ther,2004,3(2):180- 183.
[46]赵杨,温放,于月新等,survivin mRNA和caspase3 mRNA在卵巢上皮性癌中的表达及意义.中国医科大学学报,第35卷,第1期,2006年2月63-64
[47]Tamm I,Wang Y,Sausville E,et al.IAP - family protein survivin in2hibits caspase activity and apoptosis induced by Fas(CD95),Bax,cas2pases,and anticancer drugs[J].Cancer Res,1998,58(23):5315-5320,
[48]Suzuki A,Ito T,Kawano H,et al.survivin initiates procaspase 3/P21complex formation as a result of interaction with Cdk4 to resist Fas -mediated cell death[J].Oncogene,2000,19(10):1346-1353.
[49]Pietenpol JA,Stewart.ZA.Cell cycle checkpoint signaling:Cell cycle arrest versus apoptosis[J].Toxicology,2002,27(1812182):475 - 481
[50]史惠蓉,兰莉,乔玉环,等.卵巢癌组织中Survivin和PCNA的表达[J].郑州大学学报(医学版),2004;39(4):552-554.
[1]Salvesen GS,Duckett CS. IAP p roteins: blocking the road to death's door[ J ]. Nat RevMol Cell Biol, 2002, 3 (6) : 401 - 410.
[2]Altieri DC.A novel anti-apoptisis gene ,survivin,expressed in cancer and lymphoma J .Nat Med,1997,(8):917-921.
[3]Mahotka C,Wenzel M,Springer E, et al .Survivin-delta Ex3 and surviving-2B:two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.Cancer Res 1999,Decl5;59(24):6097-6102. Res,1998,Decl;58(23):5315-5320.
[4] Caldas,H. et al. Survivin splice variants regulate the balance between proliferation and cell death. Oncogene, 2005, 24, 1994-2007.
[5]Caldas,H. et al. Survivin 2alpha: a novel survivin splice variantexpressed in human malignancies. Mol. Cancer, 2005,4,11.
[6]Iamml, WangY, SausvilleED, etal.lAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anticancer drugs. Caneer Res, 1988, 58:5315-5320
[8]Cryns,V. et al. Proteases to die for. Genes Dev., 1999,12,1551-1570.
[9]Deveraux,Q.L. et al. IAP family proteins—suppressors of apoptosis.Genes Dev.,1999,13,239-252.
[10] Li,F. et al. The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycledependent expression.Cancer Res., 1999,59,3143-3151.
[11]chen J, Wu W,Tahir SK, et al.Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage- independent growth.NeoPlasia, 2000, 2(3):235-241
[12] O'Connor DS, SehechnerJS, AdidaC, et al.Control of apoptosis cells.Am J Pathol, 2000, 156(2):393-398
[13]LI F, Ambrosini G, Chu EY, et al.Control of aoptosis and mitotic spindle checkpoint by surviving.Nature, 1998, 396(6711):580-584
[14] Fukuda,S. et al. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Then, (2006) 5,1087-1098.
[15]Mesri,M. et al. Suppression of vascular endothelial growth factormediated endothelial cell protection by survivin targeting. Am. J. Pathol.(2001) 158,1757-1765.
[16] Altznauer,F. et al. Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils. J. Exp. Med. (2004)199,1343-1354.
[17]Xing,Z. et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med., (2004)199, 69-80.
[18]Gurbuxani,S. et al. Differential requirements for survivin in hematopoietic cell development. Proc. Natl Acad. Sci. USA, (2005) 102, 11480-11485.
[19]Fukuda,S. et al. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(t) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood, (2001)98.2091-2100.
[20]Deguchi,M. et al. Expression of survivin during liver regeneration. Biochem.Biophys. Res. Commun., (2002) 297, 59-64.
[21] Chiou,S.K. et al. Survivin expression in the stomach: implications for mucosal integrity and protection. Biochem. Biophys. Res. Commun., (2003) 305, 374-379.
[22]Wang,Y. et al. Survivin expression in rat testis is up-regulated by stem-cell factor.Mol. Cell Endocrinol., (2004) 218, 165-174.
[23]Altieri,D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene, (2003) 22, 8581-8589.
[24]Florrel,S.R. et al. Proliferation, apoptosis, and survivin expression in a spectrum of melanocytic nevi. J. Cutan. Pathol., (2005) 32, 45-49.
[25]Vetter,C.S. et al. Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions. Arch. Dermatol. Res. (2005) 297, 26-30.
[26]Rohayem J, Diestelkoetter P, Weigle B, et al.Antibody response to the tumor-associated inhibitor of apoptosis protein surviving in cancer patients.Cancer Res, 2000, 60:1815-1817
[27]Tanaka K, Iwamoto S, Gon G, et al.Expression of surviving and its relationship to loss of apoptosis in breast carcinomas.Clin Caneer Res, 2000, 6:127-134
[28]Grosstnan D, McNiff JM, LiF, et al.Expression and targeting of the apoptosis inhibitor, surviving, inhuman melanoma.J Invest Dermatol, 1993, 113(6): 1076-1081
[29]Monzo M, jRosell R, Felip E, Astudillo J, et al.A novel Anti-apoptosis gene:re-expression of surviving messenger RNA as a prognosis marker in non-small-cell Lung cancers.J Clin Oncol, 1999, 17(7):2100-2104
[30]Olie RA, Simoes-Wust AP.Baumann B, et al.Anovel antisense oligonucleotide Targeting surviving expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.Cancer Res, 2000, 60:2805-2809
[31]SaitohY, YaaginumaY, Ishvikawa M.Analysis of Bel-2, Bax and Survivin genes in uterin cancer.Int J Oneol, 1999, 5(1):137-141.
[32]Tringler B, Lehner R, Shroyer KR, etal. Immunohistochemical Loealization of survivin in Serous tumors of the ovary.Appl Immunohistochem Mol Mophol, 2004,Mar:12(1):40-43
[33]Sui L, Dong Y, Ohno M, etal. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.Int J Oncol ,2002:21(2):315-320.
[34]Ambrosini G, Adida C, Sirugo G, et al.Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting.J.BiolChem, 1998 Mayl: 273 (18):11177-11182.
[35]Mesri M,Wall NR, LiJ, et al. Cancer genethera by using a survivin mutant adenovirus [J].J Clinhivest, 2001, Oct;108(7):981-990.
[36]Sehmitz M, Diestelkoetter P, weigle B, et al.Gene ration of surviving-specific CD8+T effeetor cells by dendritic cells pulsed with Protein or selected peptides.Caneer Res, 2000, 60(17):4845-4849
[37]Cogoni C, Maeino G.Post-transcriptional gene silencing across kingdoms[J].Genes Dev, 2000, 10:638-643.
[38]Guru T.A silence that speaks volumes[J].Nature, 2000, 404:804-808.
[39]Hammond SM, Caudy AA, Harmon GJ.Post-transcriptional gene sileneing by double- stranded RNA[J].Nature Rev Gen, 2001, 2:110-119.
[40]Napoli C.Lemieux C, Jorgensen R.Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression ofhomologous genes in trans[J] .Plant Cell, 1990, 2:279-289.
[41]Jorgensen RA, Cluster PD, English J, et al.Chalcone synthase cosuppression phenotypes in petunia fiowersxomparison of sensevs, antisense constructs and single-copy vs, complext-DNAs equences[J] .Plant Mol Biol, 1996, 31:957-973.
[42]Ingelbreeht 1, Van Houdt H, Van Montagu M, et al.Posttranscriptional silencing of reporter trans genes in tobacco correlateswith DNA methylation[J].Proc Nat lAcad Sci USA, 1994, 91:10502-10506.
[43]Cogoni C, Irelan JT, Sehumaehe M, et al.Transgene silencing of theal-1 gene in vegetative cells of Neurospora is mediated by cytoplasmic effector and does not depend on DNA-DNA interactions or DNA methylation[J]. EMBOJ , 1996,15:3153-3163.
[44]Guo S, Kempheus KJ.Par-1, a gene required for establishing polarity in C.elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed [J].Cell, 1995, 81:611-620.
[45]Fire A, Xu S, Montgomery MK, et al.Potent an dspecific genetic interference by Double-stranded RNA in Caenothabditis elegans[J].Nature, 391:806-811.
[46]Timmons L, Fire A.Spceific interference by ingested dsRNA[J].Natufe, 1998,395:854.
[47]Timmons L, Court D, Fire A.Ingestion of baeterially expressed dsRNAs can produce spceific and potent genetic interference in Caenothabditis elegans [J]. Gene,263:103-112.
[48]Hunter CP.Shrinking the black box of RNAi[J].Current Biology, 2000 , 10:R137-R140.
[49]Sharp PA.RNA interference-2001[J].Genes Dev, 2001, 15:485-490.
[50]Hamilton AJ,Baulcombe DC.A species of small antisense RNA in posttranseriptional gene silencingin plants[J].Scienee,1999,286:950-952.[51]Zamore PD,Tuschl T,Sharp PA,et al.RNAi:double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21to23 nucleotide intervals[J].Cell,2000,101:25-33.
[52]Hutvagner G,Zamore PD.RNAi:nature abhors a double-strand[J].Curr Opin Genetics & Development,2002,12:225-232.
[53]Nykanen A,Haley B,Zamorep D.ATP requirements and small interfering RNA structure in the RNA interferenee pathway[J].Cell,2001,107:309-321.